0
0
1/20/23 at 10:21pm
Organization
Ars Technica
Author
Beth Mole
28 words
0
Comments
Shkreli's latest company, Druglike, may run afoul of his lifetime pharma ban.
You are the first to view
https://arstechnica.com/science/2023/01/ftc-shkreli-may-have-violated-lifetime-pharma-ban-should-be-held-in-contempt/
Create an account
or login to join the discussion